Carbapenem Resistance in Enterobacteriaceae

1
Carbapenem Resistance in Enterobacteriaceae

• Jean B. Patel, PhD, (D)ABMM
• Leader, Antimicrobial Resistance Team
• Division of Healthcare Quality Promotion

2
Carbapenems
3
Spectrum of Activity
4
How are Carbapenems Used?

• Uses by Clinical Syndrome
• Bacterial meningitis
• Hospital-associated sinusitis
• Sepsis of unknown origin
• Hospital-associated pneumonia

• Use by Clinical Isolate
• Acinetobacter spp.
• Pseudomonas aeruginosa
• Alcaligenes spp.
• Enterobacteriaceae
• Mogenella spp.
• Serratia spp.
• Enterobacter spp.
• Citrobacter spp.
• ESBL or AmpC E. coli and Klebsiella spp.

Reference Sanford Guide
5
Emerging Carbapenem Resistance in Gram-Negative
Bacilli

• Significantly limits treatment options for
  life-threatening infections
• No new drugs for gram-negative bacilli
• Emerging resistance mechanisms, carbapenemases
  are mobile,
• Detection of carbapenemases and implementation of
  infection control practices are necessary to
  limit spread

6
Carbapenem Resistance Mechanisms
7
Carbapenemases
8
Carbapenemases in the U.S.
9
Klebsiella Pneumoniae Carbapenemase

• KPC is a class A b-lactamase
• Confers resistance to all b-lactams including
  extended-spectrum cephalosporins and carbapenems
• Occurs in Enterobacteriaceae
• Most commonly in Klebsiella pneumoniae
• Also reported in K. oxytoca, Citrobacter
  freundii, Enterobacter spp., Escherichia coli,
  Salmonella spp., Serratia spp.,
• Also reported in Pseudomonas aeruginosa
  (Columbia)

10
Susceptibility Profile of KPC-Producing K.
pneumoniae
11
KPC Enzymes

• Located on plasmids conjugative and
  nonconjugative
• blaKPC is usually flanked by transposon sequences
• blaKPC reported on plasmids with
• Normal spectrum b-lactamases
• Extended spectrum b-lactamases
• Aminoglycoside resistance

12
KPCs in Enterobacteriaceae
Pseudomonas aeruginosa Columbia Puerto Rico
13
Geographical Distribution of KPC-Producers
Frequent Occurrence Sporadic Isolate(s)
14
Geographical Distribution of KPC-Producers in New
Jersey
15
KPC Outside of United States

• France (Nass et al. 2005. AAC 494423-4424)
• Singapore (report from survey)
• Puerto Rico (ICAAC 2007)
• Columbia (Villegas et al. 2006. AAC 502880-2882
  ICAAC 07)
• Brazil (ICAAC 2007)
• Israel (Navon-Venezia et al. 2006. AAC
  503098-3101)
• China (Wei Z, et al. 2007. AAC 51 763-765)

16
Inter-Institutional Inter-State Spread of
KPC-Producing K. pneumoniae
17
Intra-institution, Interspecies KPC Plasmid
Transfer
Cf Ko
Cf Ko
18
Laboratory Detection of KPC-Producers

• Problems
• 1) Some isolates demonstrate low-level carbapenem
  resistance
• 2) Some automated systems fail to detect
  low-level resistance

19
Susceptibility of KPC-Producers to Imipenem
S
I
R
12 of isolates test susceptible to imipenem
20
Susceptibility of KPC-Producers to Meropenem
S
I
R
9 of isolates test susceptible to meropenem
21
Susceptibility of KPC-Producers to Ertapenem
S
I
R
None of the isolates test susceptible to ertapenem
22
Can Carbapenem Susceptibility of I or R Detect
KPC-Producers?
N 76 K. pneum, K. oxy, E. coli 31
KPC-producers 45 non-KPC producers
23
CAP Results (D-05)KPC-producing Klebsiella
pneumoniae
24
Carbapenem MIC 2 mg/ml to Detect KPC-producers
N 76 K. pneum, K. oxy, E. coli 31
KPC-producers 45 non-KPC producers
25
When to Suspect a KPC-Producer

• Enterobacteriaceae especially Klebsiella
  pneumoniae that are resistant to
  extended-spectrum cephalosporins
• MIC range for 151 KPC-producing isolates
• Ceftazidime 32 to gt64 mg/ml
• Ceftriaxone 64 mg/ml
• Cefotaxime 64 mg/ml
• Variable susceptibility to cefoxitin and cefepime

26
Reading Disk Diffusion Etest
27
Phenotypic Tests for Carbapenemase Activity

• Modified Hodge Test
• 100 sensitivity in detecting KPC also positive
  when other carbapenemases are present
• 100 specificity

Procedure described by Lee et al. CMI, 7, 88-102.
2001.
28
Modified Hodge Test
Lawn of E. coli ATCC 25922 110
dilution of a 0.5 McFarland suspension
Test isolates
Imipenem disk
Described by Lee et al. CMI, 7, 88-102. 2001.
29
Modified Hodge Test

• Preliminary results suggest that any of the three
  carbapenem disks work in the Modified Hodge Test

30
What Labs Should Do Now

• Look for isolates of Enterobacteriaceae
  (especially K. pneumoniae), with carbapenem MIC
  2 mg/ml or nonsusceptible to ertapenem by disk
  diffusion
• Consider confirmation by Modified Hodge Test
• Can submit initial isolate to CDC via NJ State
  Lab for confirmation by blaKPC PCR if
  KPC-producers not previously identified in
  hospitals isolate population
• Alert clinician and infection control
  practitioner to possibility of mobile
  carbapenemase in isolate

31
KPC Questions

• If I have detect KPC-production, should I change
  susceptible carbapenem results to resistant?
• Not enough data to make a clear recommendation
• Clinical outcomes data will be necessary

32
Testing Other Drugs

• Tigecycline
• Test by Etest if possible disk diffusion tends
  to overcall resistance
• No CLSI breakpoint, but there are FDA breakpoint
• Susceptible 2 mg/ml
• Intermediate 4 mg/ml
• Resistant 8 mg/ml

33
Testing Other Drugs

• Polymixin B or Colistin
• Could test either, but colistin used clinically
• Disk diffusion test does not work dont use!
• Etest works well, but not FDA cleared
• Broth microdilution reference labs
• Breakpoints - none
• MIC 2 mg/ml, normal MIC range
• MIC 4 mg/ml indicates increased resistance

34
Acknowledgements

• Fred Tenover
• Roberta Carey
• Kamile Rasheed
• Kitty Anderson
• Brandon Kitchel
• Linda McDougal
• David Lonsway
• Jana Swenson

• Arjun Srinivasan
• Susan Mikorski